Antibody Hits Library
Over the past several years, our team has built up advanced technology platforms and specialized animal models to facilitate antibody discovery, pharmacologic validation, and ADC development. The efficiency of our gene editing and in vivo antibody discovery platforms has allowed our teams to systematically discover, screen, and validate new antibody hits in-house for over 1,000 popular drug targets. This unique, integrated antibody discovery technology platform is strategically designed to accelerate the process of antibody candidate selection in the following ways:
- In vivo natural selection to maximize developability
- Fully human antibody mice to eliminate need for humanization
- Generating cross-species reactivity using knockout RenMice®
- Prioritizing in vivo efficacy screening for I/O targets
- Enforcing a human common light chain for bispecific antibody/bispecific ADC development
Overview of Project Integrum: A Large-Scale Antibody Discovery Initiative
Biocytogen’s fully human antibody sequences were generated by proprietary RenMice® strains, each engineered to lack a certain drug target gene. Over the past 4 years, over 900 target antibody discovery projects have been completed (with 40+ in the PCC to IND stages), establishing a library of over 400K fully human antibody sequences available for evaluation and out-licensing to pharmaceutical and biotechnology companies.
Using Biocytogen’s pharmacology platform, fully human antibodies are screened in vitro and in vivo for preliminary, safety, and other parameters to ensure specificity, affinity, and other physiochemical properties are desirable.
Subsequently, screened monoclonal antibodies can also be developed as bispecific/multispecific antibodies, cell engagers, bispecific antibody-drug conjugates (bsADCs), nanobodies, TCR-mimic antibodies, and cell therapies.
Learn more about our RenMice® technology platforms:
- Monoclonal Antibody Platform – RenMabTM
- BsAb Discovery Platform
- Bispecific ADC Platform
- Nanobody Platform
- TCR-Mimic Antibody Platform
- Anti-GPCR Antibody Technology Platform
Collaboration Models
- Antibody Out-licensing
- Antibody Co-Development
- Antibody Transfer
- Technology Platform Out-licensing
Out-licensing Opportunities For Your Pipeline
We are now offering out-licensing and co-development opportunities for these antibody hits and leads to the global biopharmaceutical community.
Contact us at [email protected] for more details about our platform’s capabilities and the current products available for your target.
Therapeutic Antibody Targets
Established partnerships
Our established partnerships include ~150 therapeutic antibody co-development/out-licensing/transfer agreements, ~50 target-nominated RenMice licensing projects and 5 pipeline-based co-development.
Disclosed Partners
Worldwide antibody assets or platform partners include Gilead, Merck KGaA, Janssen, Xencor, ADC Therapeutics, Neurocrine Biosciences, Radiance Biopharma, RemeGen and BeiGene.
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
